Article

GSK3β Inhibition Synergizes with PARP Inhibitors through the Induction of Homologous Recombination Deficiency in Colorectal Cancer

2020-08-01

Abstract excerpt

<h4>Background: </h4> Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in limited objective response rate (≤ 60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistance in this subset of patients to PARP inhibitors (PARPi). To overcome resistance to PARPi and to broaden their clinical use, we performed high-throughput scr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 887f6bb8-13e9-5f7f-b640-3d174c9f1e93
DOI: 10.21203/rs.3.rs-48785/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

GSK3β Inhibition Synergizes with PARP Inhibitors through the Induction of Homologous Recombination Deficiency in Colorectal CancerDOI 10.21203/rs.3.rs-48785/v1Read

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancerSemantic proximity Read

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal CancerSemantic proximity Read

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.Semantic proximity Read

Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.Semantic proximity Read

LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repairSemantic proximity Read

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.Semantic proximity Read

CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated TumorsSemantic proximity Read

PARP9-PARP13-PARP14 axis tunes colorectal cancer response to radiotherapySemantic proximity Read

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer ModelsSemantic proximity Read

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?Semantic proximity Read

PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.Semantic proximity Read

Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of CancerSemantic proximity Read